Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | LTA4H | P09960 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446482 | 0.95 | IDO1 (0.62) | IDO1MAOAMAOBLTA4HLMNA | |
| Lithium Ion SCHEMBL7446478 | 0.93 | IDO1 (0.59) | IDO1MAOAMAOBLTA4HLMNA | |
| SCHEMBL636168 | 0.86 | ALDH1A1 (0.47) | IDO1MAOAMAOBLTA4HALDH1A1 | |
| SCHEMBL15929631 | 0.86 | ALDH1A1 (0.47) | IDO1MAOAMAOBLTA4HALDH1A1 | |
| SCHEMBL457634 | 0.86 | MAOA (0.74) | MAOAMAOBLTA4HLMNACYP2A6 | |
| SCHEMBL9242729 | 0.86 | MAOA (0.74) | MAOAMAOBLTA4HLMNACYP2A6 | |
| SCHEMBL9294674 | 0.86 | ALDH1A1 (0.47) | IDO1MAOAMAOBLTA4HALDH1A1 | |
| SCHEMBL30385926 | 0.83 | MAOA (0.70) | MAOAMAOBLTA4HLMNACYP2A6 | |
| SCHEMBL48247 | 0.83 | — | — | |
| SCHEMBL11540372 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-2144604-B1 | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 | CONATUS PHARMACEUTICALS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| CN-101668520-A | Methods for the treatment of liver diseases | CONATUS PHARMACEUTICALS INC | 2010-03-10 | — | — | CN | disclosed |
| EP-2144604-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | Conatus Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008106166-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106167-A1 | COMBINATION THERAPY COMPRISING MATRIX METALLOPROTEINASE INHIBITORS AND CASPASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207569-A1 | Methods for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-6110964-A | FOR TREATING ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, EMPHYSEMA, ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ALZHEIMER'S DISEASE, ORGAN TRANSPLANT TOXICITY, CACHEXIA, CANCER | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999067255-A1 | PROPENYL CEPHALOSPORIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999052910-A1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| CN-1160045-A | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 1997-09-24 | — | — | CN | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
| US-4156011-A | TREATMENT OF CARDIOVASCULAR DISORDERS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | IDO1 2311/4885MAOA 3095/4885MAOB 491/4885 |
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | MMP10, MMP3, GOT2 | IDO1 1794/4885MAOA 1119/4885MAOB 784/4885 |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | MMP10, MMP3, GOT2 | IDO1 1794/4885MAOA 1119/4885MAOB 784/4885 |
| US-20080207569-A1 | Methods for the treatment of liver diseases | MMP1, PYGL, MMP8 | IDO1 1413/4885MAOA 445/4885MAOB 275/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | IDO1 3778/4885MAOA 4020/4885MAOB 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.